J Korean Ophthalmol Soc.  2022 Nov;63(11):910-917. 10.3341/jkos.2022.63.11.910.

The 2021 Questionnaire Survey of the Korean Uveitis Society: Current Trends of Uveitis Diseases

• Kim SH
• Park JH
• Ryoo NK
• Kong MG
• Song SJ
• Ham DI
• the Korean Uveitis Society

• KMID: 2535892
• DOI: http://doi.org/10.3341/jkos.2022.63.11.910

Abstract

Purpose
To report the results of a 2021 questionnaire survey assessing the current trends and practice patterns in the treatment of uveitis, conducted by the Korean Uveitis Society (KUS).
Methods
To understand the current treatment and trends for uveitis in Korea, a total of 11 questions were surveyed in November 2021 among 300 members of the KUS. This survey comprised 11 multiple choice and dichotomy questions.
Results
Of 300 participants, 179 responded, and the response rate was 59.7%. Among the respondents, 92.7% were retina specialists and 66.9% reported less than 10% of uveitis patients among outpatients. As imaging tests performed in patients with anterior uveitis, fundus photography and optical coherence tomography were typically performed (83.8% vs. 73.2%, respectively). The frequently performed blood tests for general screening were complete blood count, blood chemistry test, erythrocyte sedimentation rate, and C-reactive protein (89.9% vs. 86.2% vs. 85.5% vs. 82.4%, respectively). Regarding local steroid treatment, subtenon injection was the most preferred (74.9%). Regarding systemic oral corticosteroids, 83.7% of respondents commonly used initial doses of 0.5-1 mg/kg. Cyclosporine, methotrexate, mycophenolate mofetil, and azathioprine were used for steroid-refractory uveitis patients in that order (36.2% vs. 34.8% vs. 21.7% vs. 7.3%, respectively). Concerning the currently used biologic agent, adalimumab was the most preferred, at 96.7%.
Conclusions
This survey highlights the recent trends and practice patterns in the treatment of uveitis in Korea.

Keyword

Korean Uveitis Society; Practice patterns; Survey; Trends; Uveitis